Sera from children where the medical record indicated possible immunodeficiency were excluded. Another limitation may be associated to the reported pertussis incidence peak in 2009 compared to the next years. This may have caused an increased transmission of pertussis during the first months of collection. However, when the average anti-PT IgG levels were compared among sera collected at the start of the project with sera collected at the end of the project no differences were seen (data not shown). In conclusion our data indicate that the immunity against pertussis is low 5 years after primary vaccination

and that the DTaP-booster administered at age 7–8 years gives a moderate anti-pertussis immune response that wanes to near pre-booster level in a few years. This AP24534 nmr sero-epidemiological study contributes to the conclusion that some, if not all, of the aP vaccines are inadequate to reduce the burden of pertussis. Although serious disease in the smallest, most vulnerable, not completely vaccinated children still is rare due to mass vaccinations

with aP, improved pertussis vaccines are needed. Improved vaccines should leave a longer-lasting immune response and should also harbour additional antigens that minimise the problems with vaccine escape mutant B. pertussis strains. We gratefully acknowledge Samuel Merino at the Norwegian see more Institute of Public Health, for doing the anti-FHA IgG analysis. “
“According to current vaccination policy, infants in high-risk countries should receive oral polio vaccine at birth (OPV0) followed by three doses in infancy [1]. The first dose at birth is usually given GBA3 together with Bacillus Calmette-Guérin vaccine (BCG) against tuberculosis (TB). Recently, OPV was temporarily missing in Guinea-Bissau. In this “natural experiment”, not receiving OPV0 was associated with

increased infant male survival but a weak tendency for increased mortality among females, indicating that OPV0 may have a sex-differential effect on infant mortality [2]. The BCG given at birth is known to induce a potent pro-inflammatory Th1-polarising IFN-γ response to purified protein derivate from Mycobacterium tuberculosis (PPD) [3]. However, in the “natural experiment” receiving OPV0 with BCG at birth was associated with significantly lower IFN-γ in response to PPD at 6 weeks of age, and a moderately lower likelihood of developing a BCG scar, suggesting that OPV0 may dampen the response to BCG [4]. It could be speculated that part of the lower BCG vaccine efficacy in low-income countries [5] might be due to simultaneous OPV0.